A class one drug recall has issued after the discovery of counterfeit versions of the anti-platelet clopidogrel (Plavix).
The Medicines and Healthcare products Regulatory Agency is recalling any parallel distributed stock of Lots 3098 and 6Y098 (and lot variants) of clopidogrel tablets 75 mg branded as Plavix.
The agency said: 'Initial tests show that samples only contain about 70-80% of the labelled active ingredient. In addition, a counterfeit is likely to show a different bioavailability profile and may contain harmful degradants.'
It said the counterfeits were supplied in French livery via parallel distributors into the UK supply chain. Stock presenting a patient risk may be present as French livery cartons with an overlabel applied by a parallel distributor or may have been recartoned into an English carton by the parallel distribution repacking process.